The infectious disease market is one of the largest segments of the in-vitro diagnostics (IVD) market in Indonesia, accounting for approximately 62 percent of the total market. Increased incidence of infectious diseases such as hepatitis C, HIV, TB, malaria and dengue have spurred the government to invest strongly in primary healthcare system, public hospital reforms, promotion of IVD-related technology innovation among local participants, and improved reimbursement policy, thus creating a favorable climate for market participants.
New analysis from Frost & Sullivan, Indonesian Infectious Disease IVD Market, finds that the market earned revenues of $38.6 million revenue in 2013, which is expected to reach $59.9 million in 2017. The market is segmented into immunochemistry testing, microbiology testing, and molecular diagnostics testing. Among these, the molecular diagnostics segment, which includes virology, bacteriology, molecular blood donor screening and genetic testing, is expected to grow the fastest.
Despite the strong government backing, Indonesia’s infectious disease IVD market is battling a shortage of skilled healthcare workers and laboratory facilities. This issue hampers the accurate identification, diagnosis and reporting of infectious diseases in the country.
The market is further pegged back by the long turnaround times of tests and high level of investments needed. These challenges, however, are opportunities for companies in the opposite ends of the spectrum.
"The domestic participants in the low-end market will have an edge due to their competitive pricing and faster turnaround time," explains Frost & Sullivan Healthcare Research Analyst Sanjeev Kumar. "Meanwhile, multinational companies (MNCs) in the high-end market can meet various end-user demands by offering improved localized service."
This scenario is ideal to foster partnerships between multinational companies and local participants. Collaborations between the two will create a symbiotic ecosystem, wherein local companies will gain access to capital, technology and intellectual property, and MNCs will benefit from the market reach of the domestic companies.
"Furthermore, the rise in private funding has paved the way for innovations in the Indonesia’s infectious disease IVD market," noted Kumar. "Manufacturers are already developing analyzers to meet end-user budgets, test volumes, desired breadth of test panels, and levels of automation."
The adoption of new technologies will go a long way in enhancing the patient care. For instance, highly automated analyzers with automated sample-handling features and sophisticated informatics will improve throughput and eventually, diagnostic results.
If you are interested in more information on this study, please send an email to Donna Jeremiah, Corporate Communications, at djeremiah[.]frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
Indonesian Infectious Disease IVD Market is part of the Life Sciences (lifesciences.frost.com) Growth Partnership Service program. Frost & Sullivan’s related studies include: Pulse of Telehealth 2013, the Global Emerging Interventional Cardiac Devices Market, Disinfection and Sterilization Equipment Market Trends in Asia-Pacific, and the Accountable Care Team: A Guide for Care Delivery Transformation. All studies included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.
About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation
Indonesian Infectious Disease IVD Market / P7F9-52